Related Experiment Video
Updated: Jul 4, 2025
Murine Dermal Fibroblast Isolation by FACS
Published on: January 7, 2016
Superficial CD34-Positive Fibroblastic Tumor
Raul Perret1, Isabelle Hostein1
1Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux F-33000, France.
Superficial CD34-positive fibroblastic tumors are rare, intermediate-malignancy mesenchymal neoplasms. This review covers their clinicopathology, diagnosis, molecular profile, and management.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Superficial CD34-positive fibroblastic tumor (SCFT) is a recently classified mesenchymal neoplasm.
- SCFT is characterized as a tumor of intermediate malignancy.
- It is included in the 5th edition of the WHO classification of soft tissue and bone tumors.
Purpose of the Study:
- To review current knowledge on SCFT.
- To focus on clinicopathological features, morphologic spectrum, and differential diagnosis.
- To discuss molecular profile, prognosis, and management.
Main Methods:
- Literature review of SCFT.
- Analysis of clinicopathological data.
- Review of molecular findings.
Main Results:
- SCFT presents a distinct clinicopathological and morphologic spectrum.
- Differential diagnosis includes other fibroblastic and spindle cell lesions.
- Emerging data on molecular alterations are shaping understanding.
Conclusions:
- SCFT requires careful clinicopathological evaluation for accurate diagnosis.
- Understanding its molecular profile is crucial for targeted therapies.
- Further research is needed to refine prognosis and management strategies.
More Related Videos
06:02Isolation of CD 90+ Fibroblast/Myofibroblasts from Human Frozen Gastrointestinal Specimens
Published on: January 31, 2016
08:02Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
